• Year-over-year revenue grows 10%, operating profit up 19%, non-GAAP operating profit up 19%
• Operating cash flow of $539 million
• Quarterly dividend increases 13% to $0.60 per share

Resmed Inc. announced results for its fourth quarter of fiscal year 2025, reporting strong financial and operational performance. Revenue increased by 10% to $1.3 billion, driven by robust global demand for the company's sleep and breathing health devices as well as its expanding digital health ecosystem. Gross margin improved by 230 basis points to 60.8%, and non-GAAP gross margin increased by 230 basis points to 61.4%, primarily due to procurement, manufacturing, and logistics efficiencies, as well as favorable foreign currency movements. Income from operations grew by 19%, while non-GAAP income from operations also increased by 19%. Net income for the quarter was $380 million, and diluted earnings per share was $2.58. Non-GAAP net income increased by 22% to $375 million, and non-GAAP diluted earnings per share grew by 23% to $2.55, reflecting the strong sales growth and gross margin improvement. The company generated $539 million in operating cash flow during the quarter. Resmed also announced the acquisition of VirtuOx, a leading independent diagnostic testing facility for sleep, respiratory, and cardiac conditions, which will help the company support patients earlier in their journey and deliver care in a more connected way. Additionally, the company was named the Official Sleep Partner of the Qatar Airways British and Irish Lions Tour to Australia and showcased its research at the SLEEP 2025 conference, reinforcing its leadership in sleep science and innovation.

For fiscal year 2026, Resmed expects to continue investing in innovation, scaling its digital health capabilities, and partnering with patients, providers, payers, and policymakers to ensure more people around the world have access to the care they need to sleep better, breathe better, and live longer and healthier lives.